These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 3021280)

  • 1. Saccadic eye movement deficits in the MPTP monkey model of Parkinson's disease.
    Brooks BA; Fuchs AF; Finocchio D
    Brain Res; 1986 Sep; 383(1-2):402-7. PubMed ID: 3021280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptoms and behavioral features induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in an old Java monkey [Macaca cynomolgus fascicularis (Raffles)].
    Degryse AD; Colpaert FC
    Brain Res Bull; 1986 May; 16(5):561-71. PubMed ID: 3488798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study.
    Doudet D; Gross C; Lebrun-Grandie P; Bioulac B
    Brain Res; 1985 May; 335(1):194-9. PubMed ID: 3873977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic mapping of the oculomotor system in MPTP-induced parkinsonian monkeys.
    Ho VW; Porrino LJ; Crane AM; Burns RS; Kopin IJ; Sokoloff L
    Ann Neurol; 1988 Jan; 23(1):86-9. PubMed ID: 3257855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
    C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus).
    Taylor JR; Elsworth JD; Roth RH; Sladek JR; Redmond DE
    Neuroscience; 1997 Dec; 81(3):745-55. PubMed ID: 9316026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontal cognitive impairments and saccadic deficits in low-dose MPTP-treated monkeys.
    Slovin H; Abeles M; Vaadia E; Haalman I; Prut Y; Bergman H
    J Neurophysiol; 1999 Feb; 81(2):858-74. PubMed ID: 10036286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Spontaneous saccades in MPTP-induced hemi-parkinsonian monkeys].
    Usui S; Fukuda H; Hikosaka O
    Rinsho Shinkeigaku; 1990 Nov; 30(11):1181-9. PubMed ID: 2085922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saccade responses to dopamine in human MPTP-induced parkinsonism.
    Hotson JR; Langston EB; Langston JW
    Ann Neurol; 1986 Oct; 20(4):456-63. PubMed ID: 3491578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-induced hemiparkinsonism on the kinematics of a two-dimensional,multijoint arm movement in the rhesus monkey.
    Camarata PJ; Parker RG; Park SK; Haines SJ; Turner DA; Chae H; Ebner TJ
    Neuroscience; 1992; 48(3):607-19. PubMed ID: 1351272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.
    Bezard E; Imbert C; Deloire X; Bioulac B; Gross CE
    Brain Res; 1997 Aug; 766(1-2):107-12. PubMed ID: 9359593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saccadic reaction times, eye-arm coordination and spontaneous eye movements in normal and MPTP-treated monkeys.
    Schultz W; Romo R; Scarnati E; Sundström E; Jonsson G; Studer A
    Exp Brain Res; 1989; 78(2):253-67. PubMed ID: 2599036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Changes in Saccadic Eye Movement in Hemiparkinsonian MPTP-Treated Monkeys.
    Tereshchenko LV; Anisimov VN; Shul'govsky VV; Latanov AV
    Perception; 2015; 44(8-9):1054-63. PubMed ID: 26562919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes.
    Eberling JL; Jagust WJ; Taylor S; Bringas J; Pivirotto P; VanBrocklin HF; Bankiewicz KS
    Brain Res; 1998 Sep; 805(1-2):259-62. PubMed ID: 9733979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake.
    Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR
    Neurosci Lett; 1986 Jan; 63(1):61-5. PubMed ID: 3485267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apparent unilateral visual neglect in MPTP-hemiparkinsonian monkeys is due to delayed initiation of motion.
    Bankiewicz KS; Oldfield EH; Plunkett RJ; Schuette WH; Cogan DG; Hogan N; Zuddas A; Kopin IJ
    Brain Res; 1991 Feb; 541(1):98-102. PubMed ID: 2029630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study on MPTP-induced parkinsonian animal model in rhesus monkey and the mechanism of MPTP.
    Chen SD; Xu DL; Yu HZ; Tang QM; Xu XR; Wang ZG; Liang PF
    Chin Med J (Engl); 1988 Dec; 101(12):879-83. PubMed ID: 3150735
    [No Abstract]   [Full Text] [Related]  

  • 19. The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease.
    Bloem BR; Irwin I; Buruma OJ; Haan J; Roos RA; Tetrud JW; Langston JW
    J Neurol Sci; 1990 Jul; 97(2-3):273-93. PubMed ID: 2205710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism.
    Schultz W; Studer A; Jonsson G; Sundström E; Mefford I
    Neurosci Lett; 1985 Aug; 59(2):225-32. PubMed ID: 3877257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.